Since Tau neurofibrillary tangles are the other key pathological hallmark of AD, many pharmacological strategies have been directed to the Tau pathology, by addressing Tau hyperphosphorylation through Tau kinase inhibitors such as GSK-3β inhibitors, or its aggregation by means of anti-aggregating molecules (Long and Holtzman, 2019). Here, GSK3B is linked to Alzheimer disease.